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ABSTRACT OF THESIS

ETHANOL INDUCED NEUROTOXICITY THROUGH DYSREGULATION OF
AMPK IN A FETAL ALCOHOL SYNDROME
Ethanol consumption during pregnancy is rising in the U.S., including the rate of
binge drinking. It is reported around 1 in 27 women engage in binge drinking activities
while pregnant. The third trimester is a sensitive period of neuronal growth in which
ethanol induced neurotoxicity can cause many harmful effects including Fetal Alcohol
Spectrum Disorders. It has been shown that ethanol decreases the activity of AMPK
through increasing lipid peroxidation, both of which are correlated to neurotoxicity.
AICAR is a synthetic analog of AMP which significantly increases AMPK activity and
may have beneficial effects in an organotypic hippocampal model of third trimester binge
drinking. The purpose of this study is to evaluate if pharmacologically increasing the
activity of AMPK could reduce the degree of ethanol induced neurotoxicity to provide a
potential therapeutic target for Fetal Alcohol Spectrum Disorders.
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CHAPTER 1. INTRODUCTION
1.1

Prevalence and Impact of Drinking during Pregnancy
Drinking during pregnancy can cause stillbirths, miscarriages, birth defects, and

Fetal Alcohol Spectrum Disorders (FASDs) (Denny et al., 2019). FASDs is an overarching
term that includes: Fetal Alcohol Syndrome (FAS), Partial FAS, and Alcohol-Related
Neurodevelopmental disorder (ARND) (Brown, Connor, & Adler, 2012). FASDs covers a
range of symptoms that include anatomical abnormalities, behavioral problems, and
impaired intellectual development (Denny et al., 2019). Many of these consequences are
due to permanent brain damage and will affect an individual for their lifetime (Brown,
Connor, & Adler, 2012). The leading global environmental factor that causes intellectual
disability is ethanol exposure during pregnancy. This is true for both developing and
developed countries. (Welch et al., 2016). Many individuals with FASDs go on to have
problems throughout their educational and employment experiences and have a higher
chance of being incarcerated (Brown, Connor, & Adler, 2012). In the United States, it is
estimated that 1.1%-5.0% of children in the first grade have FASDs (Denny et al., 2019).
The lifetime cost of one case of FASDs is estimated to be approximately $2 million (Luo,
2014).
Using the Behavioral Risk Factor Surveillance System the CDC collected data of
self-reported drinking behavior in 6,814 pregnant women between the ages of 18 and 44.
The most current data set from 2015 to 2017 shows that 11.5% reported drinking at least
one alcoholic drink and 3.9% reported binge drinking (4 or more drinks in one sitting) in
the past month. Of those that engaged in binge drinking the average frequency was 4.5
episodes per month, and the average intensity was 6 drinks in a sitting. Both the percentage
1

of women that engaged in drinking and binge drinking behaviors had increased from the
2011 to 2013 estimate, which was 10.2% and 3.1% respectively. Data was not given on
trimester; however, as gestation week increases the occurrence of drinking tends to
decrease. As this data was self-reported it is assumed the data is a low estimate (Denny et
al., 2019).
1.1.1

The Third Trimester as a Critical Period

The third trimester of pregnancy and the following several years after birth in
humans is characterized by rapid synaptogenesis and is a period in which ethanol can
produce deleterious effects (Saito et al., 2007). Studies have even shown that both low and
high doses of ethanol can cause changes in the cerebral vasculature by inducing brain
micro-hemorrhages when given during the third trimester. Alteration in the cerebral
vasculature have been linked to the pathophysiology of FASDs. Disruption in cerebral
vasculature can cause neuronal loss, reactive astrogliosis, and microglial activation (Welch
et al., 2016). Microglia have been shown to play a role in brain development, with early
activation potentially disrupting neurodevelopmental trajectories and/or triggering
neurodevelopmental disorders, brain injuries, and neurodegenerative disease (Saito, Saito,
& Das, 2019). Other factors that contribute to the sensitivity of ethanol during this period
include: altered neurotransmitters, altered neurotrophic factors, and a less developed
antioxidant capacity of the fetus/child (Saito et al., 2007). The last of which is thought to
be responsible for the higher levels of proinflammatory cytokines in the fetus compared to
the mother during prenatal alcohol exposure (Saito, Saito, & Das, 2019).

2

1.2

Metabolism of Ethanol
Ethanol readily passes through biological membranes so that its concentration is

broadly distributed throughout the body. It can easily enter the brain, as well as pass
through the placenta, making it teratogenic (Brown, Connor, & Adler, 2012). Ethanol can
be oxidized through alcohol dehydrogenase (ADH), catalase, and P450 (CYP2E1); all of
which are present in the brain. These reactions produce acetaldehyde, which can be reactive
with other cellular components to produce cytotoxic molecules. Aldehyde dehydrogenase
(ALDH) then oxidizes acetaldehyde to acetate. Most of the consumed alcohol is oxidized
by ADHI in the liver, though ADH1 is found in many other places including the
hippocampus in the brain. ALDH2 is located in the mitochondrial matrix, and in the brain
cortex it has a high affinity for acetaldehyde. All of these reactions reduce NAD pools,
contributing to disturbances in metabolism (Wilson & Matschinsky, 2020).
Alcohol effects nearly every tissue in the body, and intemperate consumption can
dysregulate and damage the brain, heart, liver, pancreas, lungs, bone, skeletal muscles,
endocrine, and immune systems (Luo, 2014). In the liver, alcohol leads to the inhibition of
gluconeogenesis, reduced fatty acid oxidation, decreased AMP, and increased
lactate/pyruvate ratio. In the brain ethanol significantly disrupts brain metabolism and
results in decreased glucose uptake, disrupted amino acid metabolism, stimulation of
dopaminergic activity, and inhibition of glutamatergic activity. When alcohol is consumed
it can account for 12% to 20% of cortical oxidative metabolism (Wilson & Matschinsky,
2020).
1.3 Physiological Role of AMPK
AMPK is a serine/threonine kinase that is a regulator of cellular metabolism as well
as cell polarity, autophagy, apoptosis, and cell migration. Its activation can be an adaptive
response to energy stress, where it leads to the suppression of energy consuming processes
3

and enhancement of ATP-producing pathways (Ronnett et al., 2009). As ATP remains
nearly constant in the cell, AMP is a sensitive measure of metabolic homeostasis within a
narrow range. AMPK is activated by metabolic stress when the AMP:ATP ratio is reduced
(Wilson & Matschinsky, 2020). This occurs when AMP allosterically binds to AMPK at
the Thr 172 residue. AMPK is composed of an alpha, beta, and gamma subunits with the
alpha unit being catalytic and the beta and gamma units being regulatory (Ronnett et al.,
2009). AMPK can also be activated independent of energy metabolism by reactive oxygen
species

(ROS)

including

H2O2,

calcium,

cellular

pH,

redox

status,

creatine/phosphocreatine ratio, and hormones. The three upstream kinases include liver
kinase B1 (LKB1), TGFB-activated kinase 1(TAK1), and calcium/calmodulin-dependent
protein kinase B (CAMKK2) (Ronnett et al., 2009).
When AMP is decreased, the reduction in AMPK causes downregulation in
mitophagy, mitochondrial synthesis, glycolysis, fatty acid oxidation, autophagy, and
protein synthesis. It also changes gene expression, and causes an upregulation in
gluconeogenesis, fatty acid synthesis, and inflammation. Most of the studies involving
AMPK focus on its upregulation in conditions such as exercise and hypoxia (Wilson &
Matschinsky, 2020). AMPK is a major regulator of lipid metabolism as it prevents the
conversion of acetyl Co-A to malonyl-CoA, which is the rate limiting enzyme in fatty acid
biosynthesis. Sterol regulatory element-binding protein 1 (SREBP-1), a major regulator of
fatty acid metabolism, is regulated by AMPK. (Saito et al., 2007). AMPK has been shown
to be inhibited by ethanol in hepatic cells, and possibly contributes to alcoholic fatty liver.
(Wilson & Matschinsky, 2020). It has been shown that AICAR (AMPK activator) is
beneficial in models of ethanol-induced hepatic steatosis. It decreased SREBP-1c and
4

reduced fatty acid synthase (FAS), causing decreased triglyceride synthesis (Tomita et al.,
2005). AMPK also regulates CAMP-response element-binding (CREB) protein, which is
a pro-survival transcription factor (Rehman et al., 2019).
In the brain, AMPK is primarily expressed in neurons, but can be found in
astrocytes, oligodendrocytes, and microglia (Saito, Saito, & Das, 2019). It is enriched in
the cortex, hippocampus, and hypothalamus. In the hypothalamus, AMPK activity is
controlled by nutritional signals such as insulin, leptin, and ghrelin; and it has a significant
regulation over feeding behavior (Ronnet et al., 2009). AMPK in the cortex and
hippocampus is less influenced by hormonal feeding signals (Saito et al., 2007).
1.4 Ethanol’s Interaction with AMPK
In ethanol dependent individuals disruption in protein synthesis and mitochondrial
content and morphology is believed to be due to chronic suppression of AMPK (Wilson &
Matschinsky, 2020). Oxidation of ethanol and acetate increase the energy state, while
decreasing AMPK. Inhibition of AMPK through ethanol oxidation also allows for lipid
accumulation to occur. In studies in the hypothalamus, AMPK phosphorylation can
decrease by 50% due to alcohol. Suppressed AMPK reduces GLUT1, GLUT3, and
GLUT4, which are the main glucose transporters in the brain. In alcohol studies, this
reduction can be as much as 71% for GLUT1. In microvessels of the blood brain barrier
(BBB), GLUT1 plays an integral role (Wilson & Matschinsky, 2020). AS1600 is
phosphorylated by AMPK and promotes the fusion of GLUT4 with the plasma membrane,
facilitating glucose uptake (Hill et al., 2016). Ethanol also causes the aspartate-glutamate
shuttle to be reduced, which is another way in which glutamate homeostasis is disrupted
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(Wilson & Matschinsky, 2020). The functions of AMPK and the developing brain need
more clarity; however, it is apparent that AMPK is present and abundant in the developing
brain. Knockouts of AMPK β1 can lead to loss of neurons, oligodendrocytes, and astrocyte
proliferation (Saito, Saito, & Das, 2019).
1.5 Inflammation
Inflammation is a necessary defense mechanism that protects the body against
endogenous and exogenous unwanted agents, such as bacterial, viral, and damaged cells.
Microglial have a role in synaptic organization, control of neuronal excitability, and are
responsible for the innate immune response in the nervous system. Once activated the
homeostatic microglia (M0), can switch between the classical pro-inflammatory (M1) and
the alternate anti-inflammatory (M2) phenotypes. The M1 state has been well characterized
in cultured cells by treatment with lipopolysaccharide, a type of known pathogenassociated
molecular patterns (PAMPS), that mimics the outer membrane of Gramnegative bacteria.
This activates Toll-like-receptor 4 (TRL4) on microglia and initiates NFkB (Saito, Saito,
& Das, 2019).
NF-kB is a nuclear transcription factor that is important in transcription and
synthesis of inflammatory factors (Li et al., 2019). Following NF-kB activation there is the
release of proinflammatory cytokines, chemokines, and cytotoxic factors that include:
TNF-a, IL-1B, TLRs, NO, ROS, TLRs, and cytokine receptors. In contrast, the M2 state
can be triggered by the T-helper type 2 cytokines, IL-4, and IL-3. In response, they release
IL-10, transforming growth factor (TGF-B), and arginase-1 (Arg1). The M2 state helps to
clear debris, produce trophic factors, and aids in repair. It was once thought that
neurodegenerative diseases constituted a M1 phenotype; however, due to differences in
6

phenotypes, dysregulated microglia are now referred to as disease associated microglia
(DAM) or microglial neurodegenerative (MGnD) phenotypes. Microglia are often
activated by multiple signals and so it is not uncommon that M1, M2, and DAM phenotypes
are all present in an affected area. The inflammation process is also dynamic and so changes
in different states are possible (Saito, Saito, & Das, 2019).
An important component of microglial activation is the cellular energy status,
which is dependent upon mitochondrial function, glucose availability, and the glycolytic
rate. M0 microglia maintain energy through oxidative phosphorylation; however, in the
activated state microglia switch to glycolysis. Hypoxia and hyperglycemia promote glucose
utilization and the M1 state. Caloric restriction and the ketogenic diet can promote the M2
state in specific circumstances. There are several key signaling molecules that relate the
energy status to the microglial inflammatory state. NF-kB is a major contributor and drives
the pro-inflammatory state. Silent information regulator 1 (SIRT1) regulates energy
metabolism, tissue survival, and is anti-inflammatory. It is activated by AMPK and directly
inhibits NF-kB. Peroxisome proliferator-activated receptors y (PPARy) is a type II nuclear
hormone receptor that is involved in insulin sensitivity, trophic factor production,
metabolism of lipids and glucose, and is overall anti-inflammatory (Saito, Saito, & Das,
2019). It is also necessary, along with mitochondrial transcription factor A, in AMPK’s
ability to enhance mitochondrial biogenesis (Hill et al., 2016). Nuclear factor erythroid2related factor-2 (Nrf2) is a regulator of antioxidant responses, and is suppressed under
oxidative stress (Rehman et al., 2019). Triggering receptor expressed on myeloid cells 2
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(TREM2) is anti-inflammatory as well. All of these signaling molecules are linked to
AMPK, with all of them either activating or being activated by AMPK. The exception
being NF-kB, which AMPK indirectly inhibits (Saito, Saito, & Das, 2019).
1.5.1 Ethanol and Inflammation
Ethanol has been shown to induce neuroinflammation through toll-like receptor 4
(TLR4) activation of microglia (Saito, Saito, & Das, 2019). This inflammation is more
severe in younger nervous systems that are experiencing a higher degree of neuronal
plasticity

and

neurogenesis.

Excessive

consumption

of

alcohol

can

cause

neurodegeneration, and neuroinflammation is believed to play a causal role in
pathophysiology. Ethanol exposure and most other neurodegenerative diseases display
microglia-mediated neuroinflammation and proinflammatory cytokine release (Li et al.,
2019). When ethanol is given to P7 mice, it caused acute microglial activation and apoptotic
neurodegeneration (Saito, Saito, & Das, 2019).
The hippocampus has been shown to be a region that is vulnerable to
alcoholinduced structural damage. Studies have shown that all three regions of the
hippocampus experience increased TNF-a and IL-1B levels due to ethanol. In fact, it is
believed that chronic alcohol exposure keeps microglia in a phagocytic activated
proinflammatory state (M1) (Li et al., 2019).
1.5.2 AMPK and inflammation
Phosphorylated AMPK has been shown to exert anti-inflammatory and
immunosuppressive effects in many cell types and models, mainly through supporting the
polarization from the M1 to the M2 state (Saito, Saito, & Das, 2019). This is seen in both
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genetic and pharmacological manipulation of AMPK. In knockout AMPKB1-/- mice there
was increased infiltration and activation of macrophages. Metformin, which is an AMPK
activator has shown benefits in chronic inflammatory diseases and cancers that is
independent of its effects on normalizing blood glucose levels. These effects include
reducing the transcription of TNF-a and IL6. Though most of the studies that observed
inflammatory responses in cerebral ischemia and cardiac arrest, metformin was given
preemptively or concurrently with the insult rather than subsequently. Acute metformin
treatment in stroke injury was shown to be detrimental in some rodent models, in
comparison to chronic treatment with metformin which was shown to be neuroprotective.
Consequently, the timing, duration, and amount of AMPK activation may be paramount in
determining the benefits of AMPK. Compounds such as metformin, rosiglitazone,
galgeine, berberine, and resveratrol’s beneficial effects, such as reduced inflammation,
have been shown to be dependent upon the activation of AMPK (Salt & Palmer, 2012)
(Saito, Saito, & Das, 2019). This is also true for betulinic acid (BA),a pentacyclic
triterpenoid, ENERGI-F704, an AMPK agonist, as well as Balasubramide, and Salvaoic
acid C (Saito, Saito, & Das, 2019).
AMPK activation is associated with inhibition of cytokine-stimulated NF-kB
activity in cell types such as endothelial, microglial, astrocytes, hepatic stellate,
chondrocytes, neutrophils, and macrophages (Salt & Palmer, 2012). The suppression of
NF-kB activation is linked to AMPK’s ability to inhibit TNF-a, IL-1B, and IL-6 synthesis
in macrophages, and to increase IL-10(Salt & Palmer, 2012). It is also important in the
tolllike receptor 4 (TLR4) pathway which is causal in microglial activation (Li et al., 2019).
Treatment with LPS to induce TLR4 activation causes a reduction in p-AMPK levels, but
9

can be reversed by AMPK activators (Saito, Saito, & Das, 2019). AMPK has been shown
to decrease JNK phosphorylation, and subsequently ER stress. In berberine, LPSstimulated
JNK, ERK1/2 and p38 MAPK phosphorylation were inhibited in an AMPK dependent
manner in macrophages (Salt & Palmer, 2012). AMPK also reduces cyclooxygenase-2
(COX-2) and inducible nitic oxide synthase (iNOS) (Rehman et al., 2019). These antiinflammatory processes are associated with a reduction in neurodegeneration (Saito, Saito,
& Das, 2019).
1.6 Lipid Peroxidation
Studies have concluded that alcohol consumption enhances astrocyte activation and
reactive gliosis, which is characterized by an overexpression of fibrillary acidic protein
(GFAP) and the acidic calcium binding protein, S100B. Astrocytes are paramount in the
regulation of ionic environments, and their activation is often a first response to physical
and chemical insults. At low concentrations GFAP and S100B can be neurotrophic, but
elevated levels are neurotoxic (Baydas & Tuzcu, 2005).
During binge ethanol treatments in rats, there is significant brain water elevation,
producing brain edema. This is thought to be caused by upregulated expression of
astroglial-enriched

water

channel,

aquaporin-4.

The

swelling

triggers

phospholipiddependent neuroinflammation and oxidative stress, which the brain is
sensitive to, especially in the cortex and hippocampus (Moon et al., 2014) (Rehman et al.,
2019). Overactive microglia can release many neurotoxic molecules that include
proinflammatory cytokines, metalloproteinanses, nitric oxide (NO), and even more reactive
oxygen species (ROS) (Shearn et al., 2014). Lipid peroxidation occurs when oxidative
stress causes the degradation of lipids through reactions with free radicals, compromising
10

membrane integrity (Rehman et al., 2019). Ethanol administration in all age groups has
been shown to significantly increase lipid peroxidation (Baydas & Tuzcu, 2005).
Omega-6 and arachidonic acid (AA) are released from the phospholipid membrane
in response to ROS. Omega-6 can directly cause the loss of mitochondrial transmembrane
potential (MTP), and lead to apoptosis. Normally free levels of AA remain less than 10uM,
but they can increase 50-fold in response to an insult when liberated by phospholipase A2
(PLA2), a downstream target of Toll-like receptors. AA is then broken down in eicosanoid
products such as prostaglandins and leukotrienes creating an increasing cycle of
inflammatory factors. There are three gene products in the PLA2 family: calcium
dependent cytosolic PLA2 (cPLA2), calcium independent cytosolic PLA2 (iPLA2), and
secretory calcium dependent PLA2 (sPLA2). All three seem to be integral for ethanol’s
effect on AA. It has been shown that a global inhibitor of PLA2, mepacrin, reduced
neurodegeneration in an organotypic hippocampal model. As free lipids with
polyunsaturated omega-6 acyl groups result in the production of 4-Hydroxynonenal
(4HNE), Mepacrin also blocks ethanol’s potentiation of 4-HNE (Moon et al., 2104).
ROS, can disturb the structure and function of proteins, lipids, DNA, and induce
cell death (Rehman et al., 2019). Primary markers for measuring increased oxidative stress
include 4-HNE and malodialdehyde (MDA), which are produced by peroxidation of lipids
in the cellular membrane (Rehman et al., 2019). 4-HNE is an electrophile which reacts with
nucleophilic residues such as cysteine, lysine, and histamine (Shearn et al., 2014). Under
physiological conditions there is a balance between the production of free radicals and
antioxidants (Baydas & Tuzcu, 2005). As such, 4-HNE’s damage can be mitigated by
cellular controls that include enzyme mediated oxidation, reduction, and glutathione
11

conjugation (Petersen, 2004). Glutathione is the most important endogenous antioxidant in
the central nervous system (Baydas & Tuzcu, 2005). However, if the production of lipid
peroxidation is excessive these mechanisms will be overwhelmed and insufficient to
adequately handle the stressor (Petersen, 2004). In fact, reduced glutathione levels are often
observed after ethanol consumption (Baydas & Tuzcu, 2005).
Studies have shown that melatonin, which is a direct radical scavenger and so an
indirect antioxidant, can regulate energy balance through decreasing ROS and increasing
p-AMPK in a TBI model. Through increasing AMPK, it also decreased activated JNK and
ER stress (Rehman et al., 2019). In an ethanol model, melatonin restored glutathione levels,
and stabilized glial activity (Baydas & Tuzcu, 2005). 4-HNE and MDA are negative
regulators of AMPK. By decreasing lipid peroxidation levels, this allow for AMPK to
regulate energy balance within neuronal tissue; ultimately reducing the degree
neurotoxicity and neurodegeneration.
1.6.1 Ethanol and Lipid Peroxidation
Chronic ethanol consumption causes the production of reactive aldehyde species
such as 4-HNE, malondialdehyde (MDA), and acrolein (Shearn et al., 2014). In chronic
inflammatory hepatic diseases, such as alcoholic liver disease (ALD) and non-alcoholic
steatohepatitis (NASH), it has been shown that lipid peroxidation through the production
of reactive aldehyde species such as 4-HNE directly inhibits AMPK. This occurs by 4HNE
forming Michael addition adducts to the cysteine residues 130, 174, 227, and 304 of
AMPKα and cysteine residues 225 on AMPKβ. Of these, 4-HNE’s binding to Cys 130,
174, and 304 have been shown to interfere with the active Thr 172 site, substrate access,
and inhibition of ROS induced increases. Though most alcohol abuse studies report a
12

decrease in AMPK, a few have reported an increase in AMPK phosphorylation in hepatic
cells. The discrepancy may be due to inconsistencies in the concentration and duration of
ethanol, and other contributing variables such as dietary fat. In a few of the studies that
reported elevated phosphorylation of AMPKα in response to ethanol, the carbonyl adducts
created steric hinderance preventing signal transduction, effectively inactivating the
molecule, and creating a misleading statistic (Shearn et al., 2014). It is important to note
that those studies do not report a corresponding increase in ACC (Shearn et al., 2014).
4HNE, when given by itself, inhibited the effects of AICAR and H2O2 on AMPK, showing
that aldehydes can inhibit AMPK under both conditions of oxidative stress and increased
AMP(Shearn et al., 2014).
1.7 Ethanol Induced Neurotoxicity
Neurodegeneration is a detrimental outcome of many neurological diseases and
injuries that can result in reduced physiological function, reduced mental capacity, or even
death. In all of the diseases and injuries that lead to neurodegeneration there are consistent
causal factors such as dysregulation of inflammation, oxidative stress, lipid peroxidation,
and energy imbalance (Moon et al., 2014) (Rehman et al., 2019). Glial cells appear to be
the most vulnerable to neurotoxic insults; however, glial damage can cause glial-neuronal
dysfunction and lead to neuronal degeneration. Glial cells are also the most responsive to
neuroprotective treatment, which creates a sensitive period in which damage is more
readily reversed (Baydas & Tuzcu, 2005).
Studies have shown that immature neurons as well as neurons of increased aged
are significantly more intolerant of ethanol compared to a mature nervous system (Baydas
& Tuzcu, 2005). In immature neurons this is seen in the degree of neuroapoptosis and is
13

believed to be the result of an under-developed stress mitigation system, particularly as it
involves the unfolded protein response and autophagy. The developing nervous system also
has an elevated baseline of pro-apoptotic protein contributing to its vulnerability (Luo,
2014). In FASDs, ethanol is associated with a large reduction of neurons in the cerebral
cortex, hippocampus, cerebellum, and olfactory bulb (Naseer et al., 2014). The intensity of
exposure is also a factor in the degree cell death, with binge exposure being particular
detrimental (Moon et al., 2014).
Ethanol can cause excitotoxicity through overactivation of NMDA receptors from
ethanol withdrawal (Naseer et al., 2014). It can also cause damage to mitochondria, which
produces intracellular ROS. ROS can regulate autophagy, apoptosis, and activation of
NFKB. Ethanol has been shown to induce ER stress, contributing to disruptions in calcium
homeostasis. Evidence has also shown that an increase in intracellular calcium can inhibit
autophagic flux, allowing more defective proteins to remain in the cell (Luo, 2014). Other
markers of neurotoxicity that ethanol induces include cytochrome c, cleaved caspase-3, and
PARP-1(Naseer et al., 2014).
Naseer et al., showed that osmotin, a homolog of adiponectin was protective against
ethanol induced neurotoxicity in a neonatal rat hippocampus, increasing cell viability by
80%-90%. Though adiponectin is a hormone with many mechanisms of actions, protection
was shown to be through activation of AMPK by phosphorylation at Thr210. Metformin
was also shown to reduce oxidative imbalance in the brain. Other markers such as
normalized intracellular calcium levels, improved mitochondrial function, and reduced
activation of caspase-3 were seen as well. When osmotin was given subsequently with
ethanol there was a significant reduction in propidium iodide staining (marker of cell
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death); however, when osmotin was given post ethanol treatment the reduction in
neuroapoptosis was decreased.
Translational studies show that ethanol neurotoxicity in rodents can model human
fetal alcohol syndrome through markers such as apoptotic neurodegeneration. In mice,
studies have shown that the significant rate of neurodegeneration in response to ethanol
exposure abates after 14 days (Saito et al., 2007). In a comparative study between 7- and
19-day old mice, exposure to ethanol in 7-day old mice showed apoptotic
neurodegeneration as well as changes in lipid composition. Ethanol was shown to reduce
Thr 172 phospohorylation of AMPK (decreasing its activity), along with acetyl-CoA
carboxylase which is a substrate of AMPK and a lipogenic enzyme. The levels of
triglyceride, cholesterol ester, ceramide, and N-acylphophatidylethanolamine were
significantly increased as well. In comparison, the 19-day old mice displayed little
neurodegeneration and there were smaller changes in AMPK phosphorylation. Even
without ethanol, the basal activity level of AMPK is decreased in 19-day old mice
compared to 7-day old mice. It was concluded that ethanol neurodegeneration is more
significant and severe in specific developmental periods and is dependent upon lipid
composition and AMPK activity (Saito et al., 2007).
1.7.1 AMPK Reduction of Neurotoxicity
AMPK has been shown to be beneficial, providing neuroprotection, in experiments
involving ischemic, diabetic, amyotrophic lateral sclerosis (ALS), Alzheimer’s Disease,
some Parkinson models, and brain injury models. However, in the Parkinson’s (MPTP)
model, metformin has given conflicting results with some studies showing an exacerbation
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dopaminergic decline and others showing a neuroprotective effect (Saito, Saito, & Das,
2019). In AD models, AMPK was shown to decrease amyloid-β plaque, reduce
inflammation, and prevent neuronal loss. AMPK is believed to have neuroprotective effects
by reducing inflammation, restoring energy balances, enhancing autophagy, and by
activating antioxidants. The effects of increasing AMPK are more robust when the initial
insult caused a decrease in AMPK, such as in ethanol abuse and traumatic brain injury
(Saito, Saito, & Das, 2019). Insults that result in increased AMPK levels, such as ischemia,
have the potential for an added activator of AMPK to become neurotoxic (Hill et al., 2016).
Both TBI and ethanol have disturbed metabolism after insult in regions such as the
cortex and hippocampus, particularly in the CA1 region of the hippocampus (Rehman et
al., 2019). This can contribute to impairment in cognitive abilities in both situations. Hill
et. al. showed that TBI decreases CaMKKβ levels, reducing p-AMPK, which can be
reduced from 14 days to 1 month after insult. The reduction can be reversed by post-injury
administration of AICAR or metformin. In behavioral tests spatial localization was
enhanced, suggesting improved long-term memory (Hill et al., 2016). Melatonin was also
shown to reduce amyloid-β in the cortex and hippocampus of repetitive mild TBI (Rehman
et al., 2019). Other studies have reported that AMPK reduces amyloidogenic pathway in
the mouse brain (Ou et al., 2018).
AMPK and GSK-3β are negative regulators of each other (Joo et al., 2016). GSK3
has been shown to inhibit AMPK through phosphorylation. Akt has dual action of
inhibiting GSK3 and promoting AMPK activation (Beurel Grieco, & Jope, 2015). In a
study evaluating the impact of obesity as a risk factor for Alzheimer’s Disease, it was found
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that AICAR can reduce apoptosis and inhibit ER stress which reduces tau
hyperphosphorylation by GSK-3β (Kim, 2011). Hyperphosphorylation is a biomarker for
neurodegenerative diseases such as Alzheimer’s, Chronic Traumatic Encephalopathy, and
has been reported to be causal in the neurodegeneration of the developing brain when
exposed to alcohol (Saito et al., 2010). It disrupts microtubule stability, leading to
aggregation and tangles. Lithium has been shown to block ethanol-induced caspase-3
activation and tau phosphorylation through inhibiting GSK-3β. Diets that contain either a
greater degree of saturated fatty acids or alcohol both increase the levels of free fatty acids,
lipid peroxidation, inflammation, and tau hyperphosphorylation. Insults such as ischemia
and trauma follow a similar pathway. Interestingly, the protective effects of leptin on tau
hyperphosphorylation is mediated by AMPK. AICAR has even been shown to assist in the
dephosphorylation of JNK and tau (Kim, 2011).
1.8 Pharmacotherapy for FASDs
Current therapeutic interventions are only partially efficacious for treating FASDs
(Welch et al., 2016). Many focus on behavioral therapies and educational and learning
strategies. There is a high rate of comorbid mental health disorders, with attention
deficit/hyperactivity disorder (ADHD) being the most common. Though treatment with
stimulants often cause more intolerable adverse effects in FASDs individuals. Much of the
pharmacotherapy treatment is focused on controlling comorbid mental health disorders
rather than targeting FASDs, and currently this area has been studied limitedly.
Practitioners often rely on “clinical impressions” for deciding the best treatment options
for individuals with FASDs. Other comorbid mental health disorders include depression,
bipolar, anxiety, epilepsy, attachment disorders, attention and impulse control problems,
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and many other psychiatric conditions. Some evidence with antipsychotics has shown
efficacy in FASDs populations (Brown, Connor, & Adler, 2012).
1.8.1 AICAR as a Therapeutic Target
5-aminoimidazole-4caboxamide-1-b-D-ribofuranoside (AICAR) is widely used to
increase AMPK activity as its phosphorylated state, ZMP, mimics AMP (Salt & Palmer,
2012). AICAR has been shown to cross the BBB and cause AMPK phosphorylation. Both
AICAR and metformin have off-target effects, but AICAR analogs are currently being
developed to minimize side-effects. Unlike metformin, AICAR does not inhibit complex 1
of the mitochondrial respiratory chain (Hill et al., 2016).
AICAR, has been shown to exert anti-inflammatory properties, inhibiting
activation of NF-kB, TNF-a, IL1B, IL-6, and iNOS in microglial cells (Saito, Saito, & Das,
2019). It has been proven to attenuate disease progression in rodent models of autoimmune
encephalomyelitis, lung injury, and colitis (Salt & Palmer, 2012). In studies focused on
AMPK’s downregulation in alcohol abuse, it has been shown that AICAR provides
protection from alcohol induced fatty liver,and activated AMPK by AICAR is
neuroprotective when given before glutamate excitotoxicity and glucose deprivation in
cultured hippocampal neurons. However, other studies have shown that overactivation by
AMPK can also be detrimental and even pro-apoptotic in hippocampal cells in certain
conditions (Wilson & Matschinsky, 2020). Lipid peroxidation (4-HNE) was shown to be
decreased by AICAR, which is only partly explained by decreasing adipose tissue. Insulin
sensitivity has also been shown to be increased by AICAR in muscle and liver cells in
ethanol models (Tomita et al., 2005).

18

The purpose of this study is to test if the addition of AICAR to an organotypic
hippocampal model of binge drinking could compensate for the disturbance created by
lipid peroxidation and inflammation through normalizing levels and activity of AMPK,
which would theoretically mitigate the degree of neurotoxicity in a Fetal Alcohol
Syndrome Model.

Figure 1.1 Biochemical Pathway Diagram: (Arrows represent upregulation and flipped “T”
represents downregulation). This details some of the physiological signaling in response to
ethanol consumption. The second pathway to the left in bold is the focus of the thesis and
shows how ethanol leads to ROS and lipid peroxidation. This decreases AMPK and leads
to a greater degree of neurotoxicity. A point to note, even though ROS causes an increase
in AMPK, the decrease from lipid peroxidation is far greater. An increase in AMPK will
cause an upregulation in mitochondrial biogenesis, and a downregulation in GSK-3B, JNK
(a marker of ER stress), and ultimately prevent hyperphosphorylation of tau.
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CHAPTER 2. METHODS
2.1 Hippocampal Slice Culture
Hippocampi were extracted from humanely euthanized eight to ten-day old male and
female Sprague Dawley pups (Harlan Laboratories; Indianapolis, IN). Removal of the
brains was completed using an aseptic technique. Once the brains were removed, they were
immediately placed into cold dissecting media containing Minimum Essential Media
(MEM; Invitrogen, Carlsbad, CA), (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid),
(HEPES; Sigma, St. Louis, MO), streptomycin/penicillin (Invitrogen), and Amphotericin
B solution (Sigma). A midsagittal cut was made to the brains to extract the hippocampi.
Excess tissue was then cleared away using a scalpel. The hippocampi were chopped in the
direction rostral to caudal into 200um think slices using a McIllwain Tissue Chopper
(Mickle Laboratory Engineering Co. Ltd., Gomshall, UK). Slices were selected given they
met the criteria that all three major regions of the hippocampus were intact (CA1, CA3,
and DG). Slices were then placed bipore membrane inserts with four slices per membrane,
and care was taken to ensure there was no overlapping between the slices. Excess media
was removed to allow for adhesion to the membrane. The membranes were inserted into
six well plates that contained approximately 1.5 milliliter of culture medium between the
plate and the insert. The six-well plates were incubated for six days prior to treatment to
ensure complete adhesion to the membrane surface. This also allowed for damage that
occurred during the dissection process to resolve. After treatment(s) the slices were imaged
for neurotoxicity using Propidium iodide (PI) stain.
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2.2 Treatment
After allowing for the six days of adherence to the Teflon membranes, the slice
cultures were randomly assigned to the four treatment groups: Control, Ethanol, AICAR,
and Ethanol +AICAR. The media was changed for all four groups at this timepoint. The
Control and AICAR groups received control media and placed in a Tupperware container
with 50mL of distilled water. This was sealed inside a Ziploc bag, with 5% CO2 and 95%
air. The gases were changed after two days to guarantee the ratio of carbon dioxide to air
was consistent, and to account for microleakage within the bag. The Ethanol and Ethanol
+AICAR groups were given ethanol media at a concentration of 50 mM, which is
equivalent to a blood alcohol level of 0.23%. Similarly, they were placed into a Tupperware
container with 50mL of 50mM ethanol media. This was sealed in a Ziplock bag with 5%
CO2 and 95% air, and the air was replaced after two days. After a five-day period of ethanol
or control treatment the Control and Ethanol groups were given control media and the
AICAR and Ethanol+AICAR groups were given 1mM of AICAR media. Both the control
and AICAR media contained 7.48uM of PI. Imaging was completed after 24 hours of
treatment. This was repeated for experiment 1 and experiment 2.
2.3 Staining of Cultures with Propidium Iodide
To measure the degree of neurotoxicity we used propidium iodide, which is a
fluorescent, polar compound that can interpolate into DNA. As such, it is a biomarker for
cell membrane integrity and subsequently cell death. Due to propidium iodide’s polarity it
can only enter a cell if the bilayer phospholipid membrane is compromised, which occurs
during cytotoxic events. After entering, it intercalates between bases with little sequence
preference. The binding emits fluorescence (National Center for Biotechnology
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Information, 2020). Cultures were imaged using a Leica DMIRB microscope (W.
Nuhsbahm Inc.; McHenry, Il, USA). Fluorescence was detected using a mercury lamp
under a 5x objective lens. The image was captured through SPOT advanced software for
Windows (version 4.0.2), which used a SPOT 7.2 color mosaic camera (W. Nuhsburg).
Optical density was analyzed using image J (National Institutes of Health, Bethesda, MD).
The CA1, CA3, and DG were all analyzed. For all images, background optical density was
subtracted from the area of interest, and the optical density was normalized to a percent of
the control to account for variability. The following formula was used where I represents
the optical density or intensity of a region, B is the background optical density, and C is
the average optical density for the control slices:

𝑝𝑝𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 𝑜𝑜𝑜𝑜 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 =

I−B
C

2.4 Statistical Analysis
Statistical analysis of the data provided a quantitative assessment of the effects the
four different treatment groups (Control, Ethanol, AICAR, and Ethanol+AICAR) had on
the degree of neurotoxicity. A Two Factor ANOVA was performed in SPSS (version 24)
comparing treatment and sex with a significance level of 𝑝𝑝 ≤ 0.05. A Fisher’s Least

Significant Difference (LSD) post hoc test was used to determine the differences between
treatment groups.
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Figure 2.1:Representative Images: All images were stained with propidium iodide and
imaged after 24 hours. Clockwise starting at the top left and going around are images
representative of the groups: Ethanol, Control, AICAR, and Ethanol+AICAR. All images
were labeled with an a, b, and c. Where a represents Cornu Ammonis 1 (CA1), b Cornu
Ammonis 3 (CA3), and c Dentate Gyrus (DG). A key is included underneath to show
minimal to maximal cell death.
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CHAPTER 3. RESULTS
3.1 Experiment 1: Ethanol and AICAR Treatment CA1
There was a significant effect of treatment in the CA1 region at 24 hours after
treatment, F(3, 176)=24.22, p<0.001(Figure 3.1.1). However, no sex effect was observed
for the CA1, p=0.071. Ethanol (M=120.02, SE= 5.30) was shown to increase cell death
(p=0.002) by 20.02% of the control (M=100.00, SE= 4.76). Both the combined treatment
of Ethanol+AICAR (M=77.68, SE=4.044) and AICAR (M=71.21, SE=3.65) decreased
cell death in comparison to the control by 22.32%(p<0.001) and 28.79%(p<0.001)
respectively. Both the combined treatment, Ethanol+AICAR and AICAR, decreased cell
death in comparison to ethanol(p<0.001). The effect size was 42.33% for the combined
treatment and 48.81% for AICAR treatment.
3.2 Experiment 1: Ethanol and AICAR Treatment CA3
There was a significant effect of treatment in the CA3 at 24 hours after treatment,
F(3,177)= 27.14, p<0.001 (Figure 3.1.2). However, no sex effect was observed for the
CA3, p=0.070. Ethanol (M=121.05, SE=4.71) was shown to increase cell death (p=0.001)
by 21.05% of the control (M=100.00, SE=5.03). Both the combined treatment of
Ethanol+AICAR (M=78.56, SE=4.65) and AICAR (M=69.30, SE=3.26) decreased cell
death by 21.44% (p=0.001) and 30.70%(p<0.001) respectively. Both the combined
treatment, Ethanol+AICAR and AICAR, decreased cell death in comparison to
ethanol(p<0.001). The effect size was 42.49% for the combined treatment and 51.74% for
AICAR treatment.
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3.3 Experiment 1: Ethanol and AICAR Treatment DG
There was a significant effect of treatment F(3,177)=28.86, (p<0.001), sex effect
F(1, 177)=13.95, (p<0.001), and sex and treatment interaction in the dentate gyrus,
F(3,177)=3.87, (p=0.01). Ethanol (M=122.44, SE=4.04) was shown to increase cell death
by 22.44% (p<0.001) of the control (M=100.00, SE=3.59) for both males and females.
Both the combined treatment of Ethanol+AICAR and AICAR decreased cell death from
the control by 23.30% (p<0.001) and 23.67% (p<0.001) respectively. However, there was
a sex difference in both groups. Females (M=84.36, SE=4.90) and males (M=69.04,
SE=4.46) from the Ethanol +AICAR group and males (M=61.03, SE=3.56) from the
AICAR group were individually found to be significant from the control. Nevertheless,
females from the AICAR group (M=97.74, SE=10.08) failed to be significant from the
control (p= 0.83). Both the combined treatment, Ethanol+AICAR and AICAR treatment
decreased cell death in comparison to Ethanol for both males and females. The effect size
was 45.74% (p<0.001) for the combined treatment and 46.11% (p<0.001) for AICAR
treatment. The sex treatment interaction occurred as AICAR was found to be more
protective for males in comparison to females for both the Ethanol+AICAR and AICAR
treatment groups, but there was no difference in sex in the Control and Ethanol groups.
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Figure 3.1: The effects of propidium iodide (PI) uptake in the CA1 region of the hippocampus 24
hours after treatment. Ethanol was shown to increase toxicity by 20.02% compared to the control
(p=0.002). The combination treatment of Ethanol+AICAR was significant from the control
(p<0.001) and decreased the toxicity by 22.32%. The AICAR treatment group decreased toxicity
by 28.79% (p<0.001) from the controls. The Ethanol+AICAR group decreased the toxicity
compared to ethanol by 42.33% (p<0.001), and AICAR had a decreased toxicity compared to
ethanol by 48.81% (p<0.001).
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*Significant from control
** Significant from ethanol
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Figure 3.2: The effects of propidium iodide (PI) uptake in the CA3 region of the hippocampus 24
hours after treatment. Ethanol was shown to increase toxicity by 21.05% compared to the control
(p=0.001). The combination treatment of Ethanol+AICAR was significant from the control
(p=0.001) and decreased the toxicity by 21.44%. The AICAR treatment group decreased toxicity
by 30.70% (p<0.001) from the controls. The Ethanol+AICAR group decreased the toxicity
compared to ethanol by 42.49% (p<0.001), and AICAR had a decreased toxicity compared to
ethanol by 51.74% (p<0.001).
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Figure 3.3: The effects of propidium iodide (PI) uptake in the DG region of the hippocampus 24
hours after treatment. Ethanol was shown to increase toxicity by 22.44% compared to the control
(p<0.001). The combination treatment of Ethanol+AICAR was significant from the control
(p<0.001) and decreased the toxicity by 23.30%. The AICAR treatment group decreased toxicity
by 23.67% (p<0.001) from the controls. However, females from the AICAR group failed to be
significant from the control (p= 0.83). The Ethanol+AICAR group decreased the toxicity
compared to ethanol by 45.74% (p<0.001), and AICAR had a decreased toxicity compared to
ethanol by 46.11% (p<0.001). The was a sex effect and a sex treatment interaction.
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CHAPTER 4. DISCUSSION
This experiment shows proof of concept that AICAR could have therapeutic
potential for treating individuals with Fetal Alcohol Spectrum Disorder. It was shown to
be protective in all three regions of the hippocampus (CA1, CA3, and DG) against
ethanol induced neurotoxicity in an organotypic hippocampal model of Fetal Alcohol
Spectrum Disorders. AICAR was also consistently protective in comparison to the
control, excluding the one exception of females in the DG. This protection is most likely
attributable to the fact that the hippocampal dissecting process induces trauma that is in
itself neurotoxic. By many of the same mechanism in which AICAR is protective against
ethanol induced neurotoxicity (reducing inflammation, regulating cellular metabolism,
etc.), AICAR may in the same way be protective against trauma from the dissections
(Saito, Saito, & Das, 2019).
This experiment also confirmed what is apparent in the scientific literature and in
clinical populations, that ethanol is indeed neurotoxic to the developing brain (Wilson &
Matschinsky, 2020) (Saito et al., 2007) (Denny et al., 2019). For all regions, ethanol
consistently increased the degree of cell death by around 20%. The cell death induced by
ethanol is most likely caused by a variety of factors that include ROS, lipid peroxidation
products, altered cellular metabolism, and inflammation. It can be observed from this
data, that the addition of AICAR, which mechanistically increases AMPK, contributed to
neuroprotection as it prevented a significant degree of cell death in comparison to the
Ethanol treatment group.
Though there was not a sex effect observed for the CA1 and CA3 regions of the
hippocampus, there was a sex effect observed in the DG. Specifically, this was a
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sextreatment interaction where males were more responsive to treatment with AICAR in
comparison to the females. When age was accounted for this was also only seen in the
eight-day old pups. The difference in these findings regionally, are most likely
attributable to the distinctions in cells types between the CA1/CA3 regions and the DG
region. The CA1 and CA3 are mainly composed of pyramidal cells, and granule cells are
mainly found in the DG (Alkadhi, 2019). The sex differences are most likely due to the
physiology of endocrine signaling of estradiol in the third trimester. The aromatization
hypothesis states that testicularly derived testosterone diffuses into the male brain where
it is locally aromatized to estradiol (McCarthy, 2008). Estradiol is then responsible for the
masculinization of the brain, with males having levels that are several folds higher than
female at this stage (Hilton, Nueza, & McCarthya, 2003). Females are protected from
masculinization effects of maternal estrogens by alpha-fetoprotein within neurons. Alphafetoprotein is a binding globulin found in late-gestation fetuses and early postnatal pups
that has a high affinity for estradiol. The effects of alpha-fetoprotein occur in the prenatal
and early postnatal periods only, creating a sensitive period. This could explain the sex
differences being present in the eight-day old pups, and absent in the ten-day old pups
when age was accounted for (McCarthy, 2008).
Interestingly, there was a study where kainic acid was given to newborn rat pups
of both sexes and then the brains were analyzed at postnatal day 7. In both males and
females, the CA1, CA2, and CA3 regions had minimal cell death; however, the DG
region the females had up to 40% cell loss. Pretreating females with estradiol was shown
to prevent this cell death and normalize the levels to that of the male counterparts.
Estradiol may have been protective against excitotoxicity in this case due to its
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modulating effects on calcium handling or its effect on increasing brain-derived
neurotrophic factor (BDNF), though the mechanism was not fully explored. This study
showed that the DG region in P7 female rats was prone to an increased neurotoxic
response given a stressor (Hilton, Nueza, & McCarthya, 2003). Though no increased
neurotoxic effects between males and females in the DG were found in this experiment
due to ethanol, females in the DG were found to respond less to treatment with AICAR.
Though it should be noted that though there was a sex difference in the DG and that
female P8 rats treated with AICAR were not significant from the control, both males and
females in the Ethanol+AICAR and AICAR groups were still significant compared to the
Ethanol group in the DG. This may suggest that there is an interaction between estradiol
and AICAR in the DG for P8 male rat pups, or that for some reason P8 females were
unable to respond as effectively to AICAR treatment in the DG. This experiment along
with Hilton, Nueza, and McCarthya’s findings suggest that males during this time may be
more protected against negative stressors, and more responsive to neuroprotective
treatment due to the effects of estradiol. Though the mechanism and region selectivity of
this finding needs further research for elucidation and confirmation.
Future directions beyond looking into the sex treatment interaction in the DG, will
include evaluating the biochemical pathway in which AICAR is protective against
ethanol induced neurotoxicity. Targets of these studies will include evaluating the ratio of
p-AMPK/AMPK in the four treatment groups: Control, Ethanol, Ethanol+AICAR, and
AICAR. Hypothetically, ethanol would decrease the ratio, AICAR would increase the
ratio, and Ethanol+AICAR would increase the ratio in comparison to Ethanol based on
the mechanism of AICAR and the results of this study. Lipid peroxidation products
31

should also be evaluated for the treatment groups to observe if lipid peroxidation, induced
by ethanol, does indeed cause a decrease in the ratio of p-AMPK/AMPK. Lastly, AICAR
should be evaluated to see if increases in the p-AMPK/AMPK ratio could reduce
inflammatory markers, possibly being a mechanism in which treatment with AICAR
limits the degree of ethanol-induced neurotoxicity. Currently, immunohistochemistry with
NeuN is being performed to confirm PI imaging. NeuN, which stains post-mitotic
neurons by marking the FOX-3 protein, is a fluorescent marker of living neurons (Duan et
al., 2016). From this analysis one will see if cell death from the PI concurs inversely with
the amount of neuronal conservation. Alternate explanations if the PI and NeuN do not
align, include that glial cell death contributed substantially to the total cell death.
In conclusion, there are many individuals with FASDs that suffer from intellectual
disabilities throughout the duration of their lives. The estimated cost of FASDs is $2
million per individual (Luo, 2014). This population is expected to increase in the coming
years, as binge drinking among pregnant women is rising (Denny et al., 2019). Currently,
there is no treatment or cure specifically for FASDs, and treatment is based on managing
symptoms (Welch et al., 2016). This study seeks to provide proof of concept and propose
a potential mechanism in which ethanol induces neurotoxicity. To this point, based on the
literature and these initial findings, ethanol may induce neurotoxicity by downregulating
AMPK, through lipid peroxidation (Shearn et al., 2014). Upregulating AMPK may
prevent neurotoxicity by reducing the amount of inflammation (Saito et al., 2010).
Though to this effect, this study only supports that AICAR, which’s mechanism of action
is increasing AMPK, is protective against ethanol induced neurotoxicity in an organotypic
hippocampal model of Fetal Alcohol Spectrum Disorders. In this model, AICAR was
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shown to be protective when given after ethanol intoxication, which is translational to a
real-world scenario in which a therapeutic is most likely given after intoxication.
However, further studies should evaluate if the protective effects of AICAR still remain if
there is a greater time between alcohol intoxication and treatment intervention, as this
would model Fetal Alcohol Spectrum Disorders and possible treatment intervention to a
greater degree. Animal studies should also be performed to evaluate if AICAR or a
similar pharmacologic intervention could be a possible therapeutic target. Nevertheless,
these results are promising in providing proof of concept that AICAR or a similar
therapeutic has the potential to become a medicinal target in the treatment of Fetal
Alcohol Spectrum Disorders.
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